Generex Biotechnology Subsidiary Olaregen Therapeutix Announces Agreement with Nexgen Medical for Distribution of Excellagen® Wound Conforming Matrix in Malaysia
Generex Biotechnology Corporation's subsidiary, Olaregen Therapeutix, has signed a Distribution Agreement with Nexgen Medical to exclusively sell the Excellagen wound care products in Malaysia. Nexgen anticipates obtaining commercial approval from the Malaysian Ministry of Health by the end of May 2021, with an initial purchase commitment of 500 units of Excellagen. The agreement could expand further into Southeast Asian markets, where demand for wound care products is rising. The company also expects a significant investment to support its sales program for Excellagen, potentially generating tens of millions in revenue.
- Exclusive distribution agreement with Nexgen Medical for Excellagen in Malaysia.
- Initial purchase commitment of 1,000 units in year one, indicating strong demand.
- Potential to expand into other Southeast Asian markets.
- Anticipated significant investment to restart sales program for Excellagen.
- None.
MIRAMAR, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) subsidiary Olaregen Therapeutix today announced that the company has executed a Distribution Agreement with Nexgen Medical Sdn Bhd, Inc. (“Nexgen”) to be Generex’s exclusive distributor to import, market and sell the Excellagen line of wound care products in Malaysia. Nexgen is coordinating the approval of Excellagen with the Malaysian Ministry of Health and expects commercial approval by the end of May 2021. Nexgen has committed to purchasing 1,000 units of Excellagen in year one, with an initial purchase of 500 units 0.8cc syringes of Excellagen.
Anthony J. Dolisi, President and Chief Executive Officer of Olaregen said, “This is an exciting day for Excellagen, as we have opened the door for international distribution channels to do business in Asia. We have collaborated with Nexgen to submit our clinical data to the Malaysian Ministry of Health in 2020, and we expect their approval by the end of May. This Distribution Agreement will also open the door to conduct business in Singapore, Thailand, Indonesia, Vietnam, Philippines, and other countries in Southeast Asia where the market for wound care products is expanding with rising income levels, increasing incidence of diabetes, and improved patient access.”
Cliff Keeling, Vice President and Chief Operating Officer of Olaregen said, “Nexgen Medical has well established connections throughout the orthopedic and podiatry communities in Malaysia, and we are very excited to work with them on our expansion into Asia. The Life Science industry in Malaysia is one of the new growth areas targeted for promotion and development by the government, so we look forward to great success.”
Terry Thompson, Chief Operating Officer of Generex Biotechnology Corporation, adds “Getting the Malaysian commitment for Excellagen is a parallel start and total buy-in to the effectiveness of our wound healing product. Excellagen is FDA approved in the United States, for seventeen indications and is important to our long-term strategy. I have been informed, with a high degree of confidence, that a current investor, is in the final stages of a financial commitment toward our restart. This investment will be used to re-establish our sales program for Excellagen on several fronts. Upon closing of this financing, we will complete our current bulk inventory. This will produce over 20,000 syringes which has a revenue potential of tens of millions of dollars. As the VA hospitals begin to re-open, we are positioned with a best-in-class product to methodically offer our wound healing product with our new international partners & building our brand starting with the VA hospital network.”
About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.
About Olaregen Therapeutics
Olaregen Therapeutix, Inc. is a regenerative medicine company focused on the development, manufacturing and commercialization of products that fill unmet needs in the current wound care market. The company aims to provide advanced healing solutions that substantially improve medical outcomes while lowering the overall cost of care. Olaregen's first product introduction, Excellagen® (flowable dermal matrix) is a topically applied product for dermal wounds and other indications. Excellagen is a FDA 510K cleared device for a broad array of dermal wounds, including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/ grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds, enabling Olaregen to market Excellagen in multiple vertical markets in bone and joint regeneration comprise the current pipeline. The company's mission is to become a significant force in regenerative medicine and advance the science of healing.
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Generex Contact:
Generex Biotechnology Corporation
Joseph Moscato
646-599-6222
Todd Falls
1-800-391-6755 Extension 222
investor@generex.com
FAQ
What is the recent agreement involving Generex Biotechnology and Nexgen Medical?
When is the expected approval for Excellagen in Malaysia?
What is the purchase commitment for Excellagen from Nexgen Medical?
What potential revenue can Generex Biotechnology expect from the Excellagen product?
